50932-22-4

Basic information

• Product Name: 9,10-dimethoxy-8-(trichloromethyl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
• Synonyms: 6H-1,3-benzodioxolo[5,6-a]benzo[g]quinolizine, 5,8-dihydro-9,10-dimethoxy-8-(trichloromethyl)-; Berberinylchloroform
• CAS NO: 50932-22-4
• Molecular Formula: C₂₁H₁₈Cl₃NO₄
• Molecular Weight: 454.7309
• Mol File: 50932-22-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 607.7°C at 760 mmHg
• Flash Point: 321.3°C
• Density: 1.53g/cm³
• Vapor Pressure: 1.03E-14mmHg at 25°C
• Refractive Index: 1.677
• CAS DataBase Reference: 9,10-dimethoxy-8-(trichloromethyl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 9,10-dimethoxy-8-(trichloromethyl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(50932-22-4)
• EPA Substance Registry System: 9,10-dimethoxy-8-(trichloromethyl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(50932-22-4)

Safety Data

• Hazardous Substances Data: 50932-22-4(Hazardous Substances Data)

Upstream product

• 67-66-3 chloroform 
• 10134-52-8 Berberinol 
• 633-65-8 berberine chloride 

Relevant articles and documents

Palmatine and Berberine isolation artifacts

Some 8-substituted derivatives of the protoberberine alkaloids palmatine (1a) and berberine (1b) have been prepared and investigated by 1D and 2D NMR spectroscopy (H-1, C-13, N-15). Complete NMR data for the 8-hydroxy (2), 8-methoxy (3), 8-ethoxy (4), and

HYDROPHILIC BERBERINE-TYPE DERIVATIVE AND APPLICATION THEREOF IN PREPARING DRUG

An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflmmatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity.

13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE

The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.